论文部分内容阅读
目的探讨埃克替尼在非小细胞肺癌(NSCLC)脑转移治疗中的疗效和安全性。方法回顾性分析2012-01-2015-01无锡市滨湖区中医院及盐城市第二人民医院收治的32例NSCLC脑转移患者的临床资料,所有患者均口服埃克替尼125mg/次,3次/d,直到疾病进展或发生不可耐受的毒副作用。结果 32例患者颅内病灶的有效率(RR)为56.25%,疾病控制率(DCR)为90.63%,颅外病灶的RR为43.75%,DCR为87.50%。中位疾病进展时间8.23个月,与脑转移灶数目具有相关性;中位总生存19.14个月,与KPS评分、脑转移灶数目具有相关性。本组患者的1年生存率为68.8%。主要不良反应为皮疹、腹泻,多为1~2级。结论埃克替尼治疗NSCLC脑转移疗效好,不良反应可耐受。
Objective To investigate the efficacy and safety of icotinib in the treatment of brain metastases of non-small cell lung cancer (NSCLC). Methods The clinical data of 32 NSCLC patients with brain metastases admitted to Binhu District Traditional Chinese Medicine Hospital of Wuxi and Yancheng Second People’s Hospital from January 2012 to January 2015 were retrospectively analyzed. All patients received imatinib 125 mg once daily, Times / d, until the disease progresses or intolerable toxic side effects. Results The effective rate (RR) of intracranial lesions in 32 patients was 56.25%, the disease control rate (DCR) was 90.63%. The extracranial lesions had RR of 43.75% and DCR of 87.50%. The median progression time was 8.23 months, which was correlated with the number of metastatic brain tumors. The median overall survival was 19.14 months, which was related to the KPS score and the number of brain metastases. The 1-year survival rate of this group of patients was 68.8%. The main adverse reactions were rash, diarrhea, mostly 1 to 2. Conclusion The efficacy of icotinib in treatment of NSCLC brain metastases is good and the side effects can be tolerated.